Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Technical brief | 28 January 2022 COVID-19 South Africa Removing intellectual-property barriers from COVID-19 vaccines and treatments for people in South Africa
UN Photo/Christopher Black Events Events | 24 January 2022 MSF statement at WHO Executive Board 150th Session 2 min
Photograph by Nikhil Roshan Press release Press release | 14 January 2022 COVID-19 MSF responds to latest WHO recommendation for a COVID-19 therapeutic, baricitinib 3 min
Newsletter Newsletter | 01 January 2022 Diabetes HIV/AIDS Tropical & neglected diseases Vaccines Our Wishlist for 2022
Photograph by Pierre Fromentin Press release Press release | 23 December 2021 COVID-19 MSF responds to FDA approval of COVID-19 drug molnupiravir 3 min
Photograph by Chris Allan Press release Press release | 22 December 2021 COVID-19 MSF responds to FDA approval of COVID-19 treatment nirmatrelvir/ritonavir 5 min
Blog Blog | 21 December 2021 Intellectual property and trade Saving lives through Doha: A medical humanitarian perspective